ํ™ˆSBMFF โ€ข OTCMKTS
์ค‘๊ตญ์ƒ๋ฌผ์ œ์•ฝ
$0.47
10์›” 23์ผ, ์˜ค์ „ 12์‹œ 20๋ถ„ 21์ดˆ GMT-4 · USD · OTCMKTS · ๋ฉด์ฑ…์กฐํ•ญ
์ฃผ์‹๋ฏธ๊ตญ ์ƒ์žฅ ์ฆ๊ถŒ
์ „์ผ ์ข…๊ฐ€
$0.47
52์ฃผ ๋ณ€๋™ํญ
$0.31 - $0.49
์‹œ๊ฐ€์ด์•ก
689.64์–ต HKD
ํ‰๊ท  ๊ฑฐ๋ž˜๋Ÿ‰
513.00
์ฃผ๊ฐ€์ˆ˜์ต๋ฅ 
-
๋ฐฐ๋‹น์ˆ˜์ต๋ฅ 
-
๊ธฐ๋ณธ ๊ฑฐ๋ž˜์†Œ
HKG
CDP ๊ธฐํ›„ ๋ณ€ํ™” ์ ์ˆ˜
B
๋‰ด์Šค
์žฌ๋ฌด
์†์ต๊ณ„์‚ฐ์„œ
์ˆ˜์ต
์ˆœ์ด์ต
(CNY)2024๋…„ 6์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
์ˆ˜์ต
79.37์–ต11.14%
์šด์˜๋น„
47.80์–ต10.58%
์ˆœ์ด์ต
15.09์–ต139.69%
์ˆœ์ด์ต๋ฅ 
19.01115.78%
์ฃผ๋‹น ์ˆ˜์ต
โ€”โ€”
EBITDA
19.75์–ต8.88%
์œ ํšจ ์„ธ์œจ
16.99%โ€”
์ด์ž์‚ฐ
์ด๋ถ€์ฑ„
(CNY)2024๋…„ 6์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
ํ˜„๊ธˆ ๋ฐ ๋‹จ๊ธฐ ํˆฌ์ž
131.79์–ต-15.93%
์ด์ž์‚ฐ
667.04์–ต1.62%
์ด๋ถ€์ฑ„
245.82์–ต-15.76%
์ด์ž๊ธฐ์ž๋ณธ
421.22์–ตโ€”
๋ฐœํ–‰ ์ฃผ์‹
182.05์–ตโ€”
์ฃผ๊ฐ€์ˆœ์ž์‚ฐ๋น„์œจ
0.26โ€”
์ด์ž์‚ฐ์ด์ต๋ฅ 
6.50%โ€”
์ž๋ณธ์ด์ต๋ฅ 
8.37%โ€”
์ˆœํ˜„๊ธˆํ๋ฆ„
(CNY)2024๋…„ 6์›”์ „๋…„๋Œ€๋น„ ๋ณ€๋™
์ˆœ์ด์ต
15.09์–ต139.69%
์˜์—… ํ˜„๊ธˆ ํ๋ฆ„
15.39์–ต15.25%
ํˆฌ์ž ํ˜„๊ธˆ ํ๋ฆ„
-10.20์–ต49.91%
์ž๊ธˆ ์กฐ๋‹ฌ ํ˜„๊ธˆ ํ๋ฆ„
-20.50์–ต-1.42%
์ˆœํ˜„๊ธˆํ๋ฆ„
-15.18์–ต43.37%
์ž‰์—ฌ ํ˜„๊ธˆ ํ๋ฆ„
10.88์–ต36.59%
์ •๋ณด
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China. Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries. Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products. Wikipedia
์„ค๋ฆฝ
2000
์›น์‚ฌ์ดํŠธ
์ง์› ์ˆ˜
24,437
๋” ์•Œ์•„๋ณด๊ธฐ
๊ด€์‹ฌ ์žˆ์„ ๋งŒํ•œ ์ฃผ์‹ ์ •๋ณด
์ด ๋ชฉ๋ก์€ ์ตœ๊ทผ ๊ฒ€์ƒ‰์–ด, ํŒ”๋กœ์šฐํ•œ ์ฆ๊ถŒ, ๊ธฐํƒ€ ํ™œ๋™์„ ๊ธฐ๋ฐ˜์œผ๋กœ ์ƒ์„ฑ๋˜์—ˆ์Šต๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ

๋ชจ๋“  ๋ฐ์ดํ„ฐ์™€ ์ •๋ณด๋Š” ๊ฐœ์ธ์—๊ฒŒ ์ •๋ณด๋ฅผ ์ œ๊ณตํ•˜๋Š” ๋ชฉ์ ์œผ๋กœ '์žˆ๋Š” ๊ทธ๋Œ€๋กœ' ์ œ๊ณต๋˜๋ฉฐ ๊ธˆ์œต ์ž๋ฌธ์ด๋‚˜ ๊ฑฐ๋ž˜ ๋˜๋Š” ํˆฌ์ž, ์„ธ๊ธˆ, ๋ฒ•๋ฅ , ํšŒ๊ณ„ ๋“ฑ์— ๊ด€ํ•œ ์ž๋ฌธ์„ ์˜๋„ํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค. Google์€ ํˆฌ์ž ์ž๋ฌธ๊ฐ€๊ฐ€ ์•„๋‹ˆ๋ฉฐ ์ด ๋ชฉ๋ก์— ํฌํ•จ๋œ ํšŒ์‚ฌ ๋˜๋Š” ์ด๋Ÿฌํ•œ ํšŒ์‚ฌ์—์„œ ๋ฐœํ–‰ํ•œ ์ฆ๊ถŒ๊ณผ ๊ด€๋ จํ•˜์—ฌ ๊ฒฌํ•ด, ์ถ”์ฒœ ์˜์‚ฌ ๋˜๋Š” ์˜๊ฒฌ์„ ๋ฐํžˆ์ง€ ์•Š์Šต๋‹ˆ๋‹ค. ๊ฑฐ๋ž˜๋ฅผ ์ฒด๊ฒฐํ•˜๊ธฐ ์ „์— ์ค‘๊ฐœ์ธ์ด๋‚˜ ๊ธˆ์œต ๋Œ€๋ฆฌ์ธ์—๊ฒŒ ๋ฌธ์˜ํ•˜์—ฌ ๊ฐ€๊ฒฉ์„ ํ™•์ธํ•˜์„ธ์š”. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ
ํ•จ๊ป˜ ๊ฒ€์ƒ‰ํ•œ ํ•ญ๋ชฉ
๊ฒ€์ƒ‰
๊ฒ€์ƒ‰์–ด ์ง€์šฐ๊ธฐ
๊ฒ€์ƒ‰ ๋‹ซ๊ธฐ
Google ์•ฑ
๊ธฐ๋ณธ ๋ฉ”๋‰ด